On Friday 24 July 2020 HIV i-Base published the sixth COVID-19 supplement to HIV Treatment Bulletin (HTB). Please see this link.

All i-Base reports are free to copy and i-Base encourages wide distribution. Please credit i-Base when distributing these reports.

This is a slightly expanded issue of HTB that covers both AIDS 2020 and related virtual meetings plus a fair number of COVID-19 developments that seemed too important to leave out. It is a mixed compilation, but hopefully useful.

This edition of HTB includes reports from the virtual AIDS 2020 conference and linked satellite meetings on COVID-19.

The main heading news from AIDS 2020 included continued reductions in the signal concerning dolutegravir and neural tube defects, further results on weight gain from the ADVANCE study, cabotegravir as PrEP in HPTN 083, and an early report of HIV remission.

As the introduction to these reports shows, interacting with the virtual conference was not always easy. Although we include links to the site in our reports, the site will only be open access (without registration) after 27 July 2020. 

The difficult website was reflected in overall attendance. Even when watching live events (and many were missed due to technical problems with the site), more than 2000 delegates were rarely online (when more than 20,000 people usually attend).

Many of the satellite workshops are easier to find and watch, and we include reports from the COVID-19 workshop on HCV drugs to treat COVID-19 and an update on remdesivir. As with the AIDS 2020 website, many of the webcasts and posters are now offline.

The rest of this extended issue includes both HIV reports and a continued focus on COVID-19.

For all the hope that coverage of COVID-19 might be less needed, this issue contains another 12 pages about coronavirus. Many important developments come from UK research – including new treatments, immune response, race and ethnicity and vaccines.

Both comments and trackbacks are currently closed.

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 660 other subscribers.

Follow us on Twitter